1-3 of 3
John Byon, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brian G. Till, MD, Steven I. Park, MD, Leslie L. Popplewell, MD, Andre Goy, MD, Elicia Penuel, PhD, Jeffrey M Venstrom, MD, Bo Liu, Guenter Fingerle-Rowson, MD PhD, John Byon, MD PhD, Paul Woodard, MD, M. Lia Palomba, MD
Journal: Blood
Blood (2015) 126 (23): 5104.
https://doi.org/10.1182/blood.V126.23.5104.5104
Published: 2015
Journal Articles

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Ekapun Karoopongse, MD, John Byon, MD, PhD, Cecilia Yeung, MD, H. Joachim Deeg, MD, A. Mario Q. Marcondes, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1543.
https://doi.org/10.1182/blood.V122.21.1543.1543
Published: 2013
Journal Articles

FLVCR Deletion Does Not Impact Normal Hematopoietic Stem Cell Function but Is Necessary for Erythroid and T-Cell Maturation and Enhances Platelet Formation

John Byon, MD, PhD, Jing Chen, MD, Raymond T Doty, PhD, Janis L. Abkowitz, MD
Journal: Blood
Blood (2011) 118 (21): 2363.
https://doi.org/10.1182/blood.V118.21.2363.2363
Published: 2011